Spero Therapeutics Inc. (NASDAQ: SPRO)
$1.51
+0.0650 ( +4.50% ) 248.4K
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Market Data
Open
$1.51
Previous close
$1.45
Volume
248.4K
Market cap
$80.98M
Day range
$1.44 - $1.53
52 week range
$0.99 - $1.89
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Oct 10, 2023 |
4 | Insider transactions | 1 | Oct 10, 2023 |
4 | Insider transactions | 1 | Sep 15, 2023 |
ars | Annual reports | 1 | Sep 01, 2023 |
def | Proxies and info statements | 8 | Sep 01, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
4 | Insider transactions | 1 | Aug 30, 2023 |
pre | Proxies and info statements | 8 | Aug 22, 2023 |